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Abstract The role of ATP as an extracellular signalling
molecule is now well established and evidence is accumulating
that ATP and other nucleotides (ADP, UTP and UDP) play
important roles in cardiovascular physiology and pathophysi-
ology, acting via P2X (ion channel) and P2Y (G protein-
coupled) receptors. In this article we consider the dual role of
ATP in regulation of vascular tone, released as a cotransmitter
from sympathetic nerves or released in the vascular lumen in
response to changes in blood flow and hypoxia. Further,
purinergic long-term trophic and inflammatory signalling is
described in cell proliferation, differentiation, migration and
death in angiogenesis, vascular remodelling, restenosis and
atherosclerosis. The effects on haemostasis and cardiac
regulation is reviewed. The involvement of ATP in vascular
diseases such as thrombosis, hypertension and diabetes will
also be discussed, as well as various heart conditions. The
purinergic system may be of similar importance as the
sympathetic and renin-angiotensin-aldosterone systems in
cardiovascular regulation and pathophysiology. The extracel-
lular nucleotides and their cardiovascular P2 receptors are now
entering the phase of clinical development.
Keywords ATP.Cardiovascular.Heart.Pathophysiology.
Purine.Pyrimidine.P2X.P2Y.Receptor
Introduction
Ever since the first proposition of cell surface receptors for
nucleotides [1, 2], it has become increasingly clear that, in
addition to functioning as an intracellular energy source, the
purines and pyrimidines ATP, adenosine diphosphate
(ADP), uridine triphosphate (UTP) and uridine diphosphate
(UDP) can serve as important extracellular signalling
molecules [3, 4] acting on 13 P2X homo- and heteromul-
timer ionotropic and 8 P2Y metabotropic receptor subtypes
[5, 6] (Table 1). To terminate signalling, ectonucleotidases
are present in the circulation and on cell surfaces, rapidly
degrading extracellular ATP into ADP, AMP and adenosine
[7, 8]. Evidence is accumulating suggesting an important role
for the purinergic system in cardiovascular regulation [9–15].
It stimulates vasoconstriction and vasodilatation, growth of
vascular smooth muscle cells and endothelial cells, angio-
genesis, is involved in vascular remodelling, stimulates
platelet aggregation, regulates coagulation, inflammation
and several aspects of cardiac function. It is involved in
blood pressure regulation, development of myocardial
infarction, heart failure and xenograft rejection. The physi-
ological effects of the purinergic signalling system are
dependent on the release of extracellular nucleotides, the
degradation by ectonucleotides, the type of P2 receptors
expressed on the cells, their desensitisation rates and their
second messengers. P2 receptors have highly specific organ
distributions and they can be rapidly up- or downregulated.
The purinergic system may be of similar importance as the
sympathetic and renin-angiotensin-aldosterone systems in
cardiovascular regulation and pathophysiology. The involve-
ment of purinergic signalling in a variety of different
cardiovascular clinical conditions has been addressed to a
limited extent previously [15–19] and the large number of
new discoveries calls for a review to summarise the most
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The research field has grown rapidly since the term P2
receptor was coined [2]. In preparation of this review more
than 2,700 references on P2 receptors and cardiovascular
regulation were found in PubMed. Among the 15 receptor
subtypes, one is the target for one of the most widely used
medical drugs—the platelet inhibitor clopidogrel (Plavix).
As will be reviewed here, several of the other 15 receptors
are promising drug targets to prevent cardiovascular disease.
Regulation of vascular tone
Vasoconstriction produced by ATP released as a cotrans-
mitter with noradrenaline (NA) from perivascular sympathet-
ic nerves was recognised early [20, 21]. However, following
the seminal discovery of endothelium-dependent vasodilata-
tion by Furchgott in the early 1980s, it was shown that ATP
acted on endothelial cells to release endothelial derived
relaxing factor [later shown to be largely nitric oxide (NO)]
resulting in vasodilatation [22] and dual purinergic neural
and endothelial control of vascular tone established [23, 24].
Neuronal regulation of vascular tone
ATP is, together with NA and neuropeptide Y (NPY), a
cotransmitter in sympathetic neurons [11, 25, 26], and
sensory-motor nerves during “axon reflex” activity release
ATP to dilate or constrict vessels [27, 28]( F i g .1). The con-
tribution of ATP to sympathetic contraction varies between
vascular beds [25]. For example, it may mediate up to 50%
of the neurogenic vasoconstriction via P2X1 receptors as
seen in mesenteric arteries [29], about 70% in rabbit saphe-
nous arteries and 100% in rabbit jejunal artery, while NA
acts as a prejunctional modulator [30]. In the renal vascu-
lature both P2X1 and P2Y2 receptors are important for
neurogenic contraction. P2X1 receptors mediate contraction
in afferent but are absent in the efferent renal arterioles [31,
32]. The result is that extracellular nucleotides selectively
influence preglomerular resistance without having an effect
on postglomerular tone. ATP is also released locally in the
Table 1 Receptor classification, intracellular signalling, ligands and selective agonists and antagonists
P2 subtype I.c. signalling Ligand Selective agonist Selective antagonist Non-selective
antagonist
P2Y1 ↑IP3 ADP (ATP) MRS2365 MRS 2179, MRS2500
P2Y2 ↑IP3 UTP = ATP MRS2498, UTPγS,
INS3717
Suramin > RB2
P2Y4 ↑IP3 UTP (=ATP in rodents) UTPγS, INS3717 – RB2 > Suramin
P2Y6 ↑IP3 UDP MRS2666,
MRS2633, UDPβS
MRS2578
P2Y11 ↑IP3, ↑cAMP ATP AR-C67085MX,
NF546
NF157 Suramin > RB2
P2Y12 ↓cAMP ADP – Clopidogrel, prasugrel, AZD6140,
INS50589, AR-C9931 (cangrelor)
P2Y13 ↓cAMP ADP – MRS2211
P2Y14 IP3 UDP-glucose,
UDP-galactose
UDP-glucose,
UDP-galactose
–
P2X1 Positive ion
channel
ATP α,β-mATP NF023, NF449 TNP-ATP, Ip5I
P2X2 Positive ion
channel
ATP – NF770 Suramin,
isoPPADS, RB2
P2X3 Positive ion
channel
ATP α,β-mATP A317491, NF110 Suramin
P2X4 Positive ion
channel
ATP Ivermectin
potentiates
– TNP-ATP
P2X5 Positive ion
channel
ATP –– Suramin, PPADS
P2X6 Positive ion
channel
ATP –– –
P2X7 Positive ion
channel
ATP – KN62, KN04, MRS2427 Coomassie
brilliant blue G
Ectonucleotidase Apyrase, human
SolCD39
ARC67156
2 Purinergic Signalling (2008) 4:1–20kidney in response to increased perfusion pressure, and in
P2X1 receptor knockout mice auto-regulatory responses in
kidney afferent arterioles are abolished, indicating an impor-
tant role in renal glomerular pressure regulation [32, 33].
Sympathetic nerves express inhibitory P2Y and P1 (A1)
receptors indicating a P2 receptor-mediated negative feed-
back loop both directly by ATP and its degradation product
adenosine [34, 35]. Ectonucleotidases are released from
sympathetic nerves together with its substrate ATP, as a termi-
nation mechanism for the signalling [36]. Another balancing
mechanism is the sympathicolytic effect seen in exercising
skeletal muscle, which is important for increased blood flow
in the working skeletal muscle during exercise, despite
sympathetic NA release that normally would reduce blood
flow. This sympathicolytic effect is mimicked by injection in
the arterial lumen of ATP and UTP, inducing a vasodilatation
that overrides sympathetic vasoconstrictor activity in human
skeletal muscle, an effect not obtained by injection of
adenosine [37], suggesting that ATP and UTP may mediate
this important physiological mechanism.
T h ef i r s te v i d e n c eo ft h ep r e s e n c eo fP 2r e c e p t o r
subtypes suggested P2X receptors onvascular smooth muscle
cells (VSMC) and P2Y receptors on endothelial cells [38].
Rat blood vessel immunohistochemistry and human mRNA
quantification have shown the P2X1 receptor to be the
highest expressed subtype in smooth muscle cells [39, 40]. It
has been difficult to prove the importance of other contractile
P2X receptors besides P2X1 due to the paucity of specific
agonists and antagonists. However, contractile effects of
UTP suggested that P2Y receptors were present on VSMCs
and mediated contraction [41]. Using selective pyrimidines
resistant to degradation, it has been possible to show that
contractile effects are mediated by both UTP-sensitive P2Y2
and UDP-sensitive P2Y6 receptors [42]. Ectonucleotidases in
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Fig. 1 P2 receptor-mediated regulation of the circulation. See text for
details. Purines and pyrimidines are released on the luminal side from
endothelial cells, platelets and red blood cells (RBC) in response to
hypoxia, acidosis, adrenaline, shear stress and other stimuli. When the
endothelial cell layer is intact, the response is vasodilatation by the
endothelial release of nitric oxide (NO), endothelium-derived hyper-
polarising factor (EDHF) and prostaglandins (Pgl). When the
endothelium is damaged, platelets accumulate, release ATP and ADP
and mediate vasoconstriction via P2 receptors on the vascular smooth
muscle cell (VSMC). On the adventitial side sympathetic and sensory
nerves mediate vasoconstriction. Extracellular nucleotides are rapidly
degraded by NTPDase1 on endothelium reducing ATP to AMP,
followed by conversion to adenosine by CD73 (not shown). In the
subendothelium NTPDase2 is present, degrading ATP to ADP,
maintaining the platelet activating and contractile effects. Ado
adenosine, CGRP calcitonin gene-related peptide, SP substance P
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reduce their contractile effects. Pyrimidine analogues more
resistant to ectonucleotidases are powerful vasoconstrictors
andupto1,000-foldmorepotentthanthe endogenousligands
[42]. Similarly, a prominent more potent UDP contraction
has been seen in NTPDase1 knockout mice, demonstrating
the protective effect of ectonucleotidases against nucleotide
contraction [43]. In human saphenous vein grafts, used
during coronary bypass, a stable UDP analogue stimulates a
strong contraction lasting for hours, which is not desensitised
[44]. The reason why the P2Y6 receptor is not desensitised is
the lack of serine residues in the C-terminal part of the P2Y6
receptor [45]. Neither α1-adrenoceptors, nor P2Y6 receptors,
are present in human coronary arteries, possibly to avoid
deleterious vasospasm during ischaemia [44].
VSMC express P2Y12 receptors that mediate contraction
after stimulation with ADP [46]. At the mRNA level, the
P2Y12 receptor is the highest expressed ADP receptor and
the second highest expressed P2 receptor in human VSMC
[46]. The contractions are not inhibited in patients medicated
with clopidogrel. However, drugs with antagonistic effects
on P2Y12 receptors that reach the peripheral circulation
(AZD6140 and INS50589), affecting both platelets and
VSMC, could be of double therapeutic benefit in their
prevention of both thrombosis and vasospasm [46].
In conclusion, extracellular nucleotides mediate vaso-
constriction when released from nerves on the adventitial
side, or when released in the lumen when the endothelium is
damaged (Fig. 1). The most important contractile receptors
on the VSMC are the ATP P2X1 receptor, the ATP/UTP
P2Y2 receptor, the UDP P2Y6 receptor and the ADP P2Y12
receptor (Fig. 1 and Table 2). To determine the relative
physiological importance of these receptor subtypes in
different human vascular beds is an important task for the
future.
Endothelial regulation
Shear stress and hypoxia are important stimuli of both ATP
and UTP release from endothelial cells [47] (Fig. 1).
Extracellular nucleotides have several important effects
mediated by activation of endothelial cells. Vasodilatation
and decreased blood pressure by release of prostaglandins
and NO has been demonstrated in several studies [5], but
P2 receptors also mediate release of endothelium-derived
hyperpolarising factor (EDHF), which relaxes VSMC by
activation of potassium channels, with subsequent hyper-
polarisation [48–50]. Both UTP and ATP reduce forearm
vascular resistance in a prostaglandin and NO independent
way [51], indicating an important role for EDHF in P2
receptor-mediated vasodilatation in man.
The P2Y1 receptor seems to be of major importance in
most vascular beds [11]. However, several other P2 receptors
are important for endothelial regulation. Pharmacology of
vasodilatation and mRNA quantification in man indicates
that P2Y2 and to a lesser degree P2Y6 also are important
endothelial P2Y receptors [40, 52]. Knockout mice experi-
ments recently confirmed this picture and demonstrated that
the P2Y4 receptor does not mediate dilatation [53]. UTP and
ATP are equipotent as vasodilators when infused in the
human forearm circulation, indicating a role for both
purinergic and pyrimidinergic receptors.
Table 2 P2 receptor expression in the cardiovascular system
P2
subtype
Endothelium VSMC Heart Platelets Red
blood
cells
Inflammatory
cells
Perivascular sensory
nerves
Perivascular sympathetic
nerves
P2Y1 High ––High (Turkey) Medium Medium (neg. feedback)
P2Y2 High High High ––High Low Possible
P2Y4 – Possible –––
P2Y6 Medium Medium High ––
P2Y11 Possible – High ––High
P2Y12 – Medium – High – Low
P2Y13 – –––High Low
P2Y14 – ––––
P2X1 – High Medium High – Medium
P2X2 – –––– High Medium (pos. feedback)
P2X3 – –––– High
P2X4 High – Low ––High
P2X5 – ––––
P2X6 – ––––
P2X7 – Possible ––Low High
Unless specified data refer to human tissue. High, medium or low expression represents an effort to summarise the results of a large number of
mRNA, protein and pharmacological studies. Dash (–) denotes lack of convincing evidence for expression. VSMC vascular smooth muscle cell
4 Purinergic Signalling (2008) 4:1–20The P2X1 receptor is not expressed on the vascular
endothelium and the evidence for other P2X receptors has
been scarce, except for the P2X4 receptor which is the
highest expressed P2 receptor in endothelium [40, 54].
Using antisense oligonucleotides the P2X4 receptor was
shown to be important for shear stress-dependent Ca
2+
influx via an ATP-dependent mechanism [55]. This indi-
cates that ATP and P2 receptors may be of importance for
shear stress-mediated effects, which is in agreement with
the well-established release of ATP from endothelial cells
during shear stress [56]. Vessel dilation induced by acute
increases in blood flow is markedly suppressed in P2X4
receptor knockout mice [57]. Thus, endothelial P2X4
channels are crucial to flow-sensitive mechanisms that
regulate blood pressure and vascular remodelling [57].
Extracellular ATP in the circulation is rapidly degraded
into ADP, AMP and adenosine by ectonucleotidases.
Vascular NTPDase1 (CD39) is an endothelial cell membrane
protein with both ecto-ATPase and ecto-ADPase activities
[8, 58]. Ectonucleotidases are also released by shear stress
from endothelial cells [59].
Reactive hyperaemia is the massive increase in blood
flow that starts when a blood vessel is opened after a period
of ischaemia. It is well known that ATP is released during
ischaemia [7, 60]. Adenosine only mediates the late phase
of the reactive hyperaemia as has been shown by infusion
of adenosine deaminase or a selective A2A antagonist [61,
62]; ADP has been shown to mediate the mid-portion and
peak of coronary reactive hyperaemia via endothelial P2Y1
receptors [63]. It has been proposed that different purines
may mediate three phases of the reactive hyperaemia [63].
According to this hypothesis, ATP would mediate the first
part of the hyperaemia via endothelial P2Y2 or P2X4
receptors. ATP would then be degraded to ADP, which
mediates peak hyperaemia via endothelial P2Y1 receptors,
followed by degradation of ADP to adenosine resulting in
late phase hyperaemia mediated via A2A receptors on smooth
muscle cells.
Red blood cells as regulators of vascular tone
The matching of oxygen supply with demand requires a
mechanism that increases blood flowinresponseto decreased
tissue oxygen levels. Several reports suggest that the red
blood cell (RBC) acts as a sensor for hypoxia and different
mechanisms have been suggested by which the deoxygenated
RBC stimulates vasodilatation [37, 64–66]. RBCs contain
millimolar amounts of ATP and possess the membrane-
bound glycolytic enzymes necessary for its production [67–
69]. ATP is released in response to reductions in oxygen
tension and pH [37, 64] (see Table 3). It has been shown in
vitro that vessels dilate in response to low O2 levels only
when blood vessels are perfused with RBCs [70]. ATP is
released in working human skeletal muscle circulation
depending on the number of unoccupied haemoglobin O2
binding sites [64, 71]. Similar results have been shown in the
coronary circulation of dogs [72]. The released ATP then
binds to P2Y receptors on the endothelium and stimulates
vasodilatation. Thus, the RBC functions as an O2 sensor,
contributing to the regulation of blood flow and O2 delivery,
by releasing ATP depending on the oxygenation state of
haemoglobin.
ADP activates a negative feedback pathway for ATP
release from human RBCs via P2Y13 receptors [73]. Since
blood consists of approximately 40% RBCs that contain a
1,000-fold higher ATP concentration than plasma (mmol/
Table 3 Release of purines and pyrimidines in the cardiovascular system
Source Endothelium VSMC Heart Platelets Red blood
cells
Inflammatory
cells
Vascular nerves
Stimuli Shear stress,
hypoxia, high
glucose
High
glucose,
hypoxia
Hypoxia Collagen,
thromboxane, other
platelet activators
Hypoxia,
adrenaline,
deformation
Infl.
activators
Sympathetic nerves,
sensory nerve collaterals
Mechanism Vesicular Unknown Unknown Vesicular Unknown Unknown
or vesicular
Vesicular
Nucleotide ATP, UTP ATP, UTP ATP, UTP ADP > ATP ATP ATP ATP
Target Endothelium
VSMC
VSMC Cardiomyocytes,
blood vessels,
intrinsic cardiac
neurons
Platelets;
endothelium
or VSMC
Endothelium VSMC,
endothelium
VSMC
Degradation NTPDase1 NTPDase2,
NTPDase1
NTPDase1 NTPDase1 NTPDase1 NTPDase1 NTPDase1
(co-released)
Stimuli represents stimuli leading to release. Mechanism refers to mechanism of release at the cellular level. Target represents the cells that are
regulated by the released purine or pyrimidine. Degradation refers to the degrading enzyme responsible for removing the purine or pyrimidine
after the release. VSMC vascular smooth muscle cell
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intracellular concentrations could have major circulatory
effects. A negative feedback system may therefore be of
great physiological importance to mitigate ATP release.
Another negative feedback system is the mechanism by
which NO inhibits ATP release from erythrocytes, illustrat-
ing how NO may turn off ATP release [74]. NO is then
scavenged by haemoglobin.
Furthermore, the previous view of the RBC as a “passive
bag that transports oxygen” is challenged. It now turns out
that it releases ATP in response to stimuli and, as with most
important signalling systems, it has a negative feedback
system to terminate its release. The described negative
feedback pathway may be important to avoid high extracel-
lular concentrations of ATP. At levels above 100 µmol/l, ATP
concentrations may exceed the catalytic capacity of ectonu-
cleotidases and could, in fact, stimulate ATP release by
increasing permeability of the RBC [75], probably via P2X7
receptors [76]. ATP may even release ATP from endothelial
cells [77]. At high concentrations of ATP, a self-sustaining
process may thus be instigated which may contribute to the
irreversible stage of circulatory shock that can develop
rapidly in severely ill patients. Similar mechanisms may be
of importance in malaria because induction of the osmolyte
permeability in Plasmodium-infected erythrocytes involves
purinoceptor signalling [78].
A mechanism of ATP release from RBCs, which has
eluded researchers for many years, has recently been
suggested by Locovei and co-workers as being mediated via
the gap junction protein pannexin-1 [79]. Erythrocytes do not
form gap junctions, instead pannexin-1 forms a mechano-
sensitive ATP-permeable channel that mediates osmotically
induced ATP release.
Hypertension
Blood pressure regulation by purinergic signalling is the net
result of balancing contractile and dilatory effects as
described above. ATP and UTP released on the luminal side,
from endothelial cells and erythrocytes, stimulate vasodila-
tation, in contrast to release from nerves on the adventitial
side, which results in vasoconstriction. ATP may also
regulate blood pressure via renal mechanisms or brain stem
regulation [31, 32].
ATP plays a significantly greater role as a sympathetic
cotransmitter in spontaneously hypertensive rats (SHR) [80,
81], and there is increased responsiveness of the renal
vasculature of isolated perfused rat kidneys to α,β-methylene
ATP in SHR [82], while mesenteric vascular contractile
reactivity to ATP via P2X1 and P2Y2 receptors is not altered
in deoxycorticosterone acetate (DOCA)-salt hypertension
[83]. In the aorta of SHR, endothelium-dependent relaxation
to ATP is impaired because of the concomitant generation of
an endothelium-derived contracting factor. Contractions to
ATP were significantly potentiated in SHR aorta [84]. In
hypertensive mature stroke-prone rats, NPY modulation of
release of NA and ATP from sympathetic perivascular nerves
in kidney vessels is impaired, which may account for the
increased nerve-mediated responses [85]. Thus, animal
models of hypertension reveal several alterations in purinergic
signalling that may contribute to the development of
hypertension.
Diadenosine polyphosphates such as Ap4A, Ap5A and
Ap6A are combinations of two adenosine molecules
connected with four to six phosphate groups. They have
been identified as vasocontractile agents [86], probably via
actions on P2X1 and P2Y2 receptors. Ap5A and Ap6A are
stored at higher levels in platelets from patients with
hypertension and may contribute to their increased periph-
eral vascular resistance [87]. Up4A is a novel endothelium-
derived vasoconstrictive factor more potent than endothelin
in renal vasoconstriction [88]. It is released upon stimula-
tion of the endothelium by acetylcholine, thrombin and
mechanical stress and can be cleaved into either ATP or
UTP to stimulate both P2X1 and P2Y2 receptors on VSMC
resulting in increased blood pressure [88].
As mentioned above, the P2X4 receptor is the most
abundantly expressed P2 receptor in the endothelium and
mediates shear stress-stimulated vasodilatation. P2X4 recep-
tor knockout mice have higher blood pressures and excrete
smaller amounts of NO products in their urine than do wild-
type mice [57]. The P2X4 receptor protein is upregulated in
the placenta in preeclampsia [89]. Thus, shear stress-
stimulated release of ATP acting on P2X4 receptors may be
important for blood pressure regulation.
The importance of P2 receptors for hypertension will
not be proven until tested in man. It would be of great
interest to perform a clinical study on the effects of P2X1,
P2Y2 or P2Y6 receptor antagonists in the treatment of
hypertension.
Pulmonary hypertension
Erythrocyte release of ATP appears to regulate pulmonary
resistance under some conditions [90], and patients with
pulmonary hypertension have been found with impaired
release of ATP from RBC [69]. Endothelium-dependent
r e l a x a t i o nt oA T Ph a sb e e nd e m o n s t r a t e di nh u m a n
pulmonary arteries [91]. On the other hand, ATP is a
mitogen for pulmonary artery smooth muscle cells, which
may be relevant for the pathophysiological basis of
pulmonary hypertension [92]. Again, the balance between
endothelial versus smooth muscle stimulation by ATP may
regulate blood pressure in different directions and we are far
from a full understanding of the role of the purinergic system
in pulmonary hypertension.
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Classic migraine is associated with two distinct vascular
changes: an initial vasoconstriction, followed by vasodilata-
tion associated with pain. It has been proposed that purinergic
signalling is involved in these changes. ATP released from
perivascular sympathetic nerves may participate in producing
the initial vasospasm mediated by P2 receptors in vascular
smooth muscle. Cerebral arteries are strongly contracted by
UTP and especially UDP via P2Y6 receptors. A UDP agonist
might therefore have similar effects as the 5-HT1D agonists
frequently used to treat migraine [93]. ATP released by
endothelial cells acting on P2 receptors on endothelial cells
mediating release of NO and producing vasodilatation may
contribute to the phase of reactive hyperaemia following
vasospasm [94]. It has been suggested that antagonists to
P2X3 receptors, which are located on nociceptive sensory
nerve endings in cerebral vessels, may be promising
candidates for anti-migraine drug development [95]. A
recent report demonstrates selective upregulation of noci-
ceptive P2X3 receptors on trigeminal neurons by calcitonin
gene-related peptide and suggests that this mechanism might
contribute to pain sensitisation in migraine [96]. P2Y
receptors on trigeminal sensory nerves have also been
implicated in pain in migraine. It has been claimed that
migraine attacks are characterised by a relative depletion of
sympathetic NA stores in conjunction with an increase in
release of ATP [97]. In a review in the Lancet in 1996,
Burnstock proposed that vascular pain, as in angina,
ischaemic muscle and pelvic pain in women, may be
initiated by ATP released from microvascular endothelial
cells during reactive hyperaemia, diffusing a short distance
to activate P2X3 nociceptive receptors on sensory nerves in
the adventitia [26].
Atherosclerosis
Atherosclerosis is the main cause of ischaemic stroke and
cardiovascular disease and is now considered to be an
inflammatory disease [98]. The formation of a plaque starts
with the accumulation of cholesterol followed by invasion of
macrophages taking up cholesterol and becoming foam cells.
The plaque can be stabilised by smooth muscle cell
formation of a fibrous cap that covers the lipid-rich region.
However, stimulation of inflammation by oxidised low-
density lipoprotein activates macrophages and dendritic cells
into antigen-presenting cells, activating T lymphocytes
resulting in release of cytokines and metalloproteinases
degrading the fibrous cap. The end result is a vulnerable
plaque and, when it ruptures, its highly thrombogenic
contents activates platelets and causes the formation of a
local thrombus occluding the artery or embolising, resulting
in ischaemic stroke or myocardial infarction. Evidence both
from basic research and from clinical studies indicates
important involvement on several levels for purinergic
signalling in the atherosclerotic process (Fig. 2). Interesting-
ly, fish oil components increase the release of ATP [99]a n d
a high cholesterol diet decreases ATP release from arteries
[100, 101].
Atherosclerosis—P2 receptor-mediated effects
on inflammatory cells
Inflammatory cells express a large number of P2 receptors
with multiple effects [102]. The final result is difficult to
predict depending on the subtype of receptor expressed by a
particular cell type and on the differentiation stage of the
cell. The most important inflammatory cells for atheroscle-
rosis are monocytes that differentiate into macrophages or
dendritic cells in the plaque, and the T-helper and
suppressor lymphocytes that coordinate the inflammatory
reaction in the plaque [98].
A large number of P2 receptors are expressed on T
lymphocytes and macrophages [14, 103] and have been
suggested to be important players in atherosclerosis [14].
Strong evidence for a functional role exists for P2X7,P 2 Y 2
and P2Y11 receptors. The P2X7 receptor is mitogenic and
anti-apoptotic for T lymphocytes [104, 105]. P2X7 is
important for release of interleukin (IL)-1 [106], tumour
necrosis factor [107]a n dL-selectin, an adhesion molecule
important for lymphocyte binding to endothelium [108]. All
of these effects are known to be important for atherosclerosis
development. The severity of arthritis is reduced in P2X7
receptor knockout mice [109] and rheumatoid arthritis is
coupled to increased incidence of myocardial infarction. It
would be of great interest to examine the P2X7 receptor
knockout mouse in an atherosclerosis model. ATP and UTP
are chemotactic for dendritic cells probably via the P2Y2
receptor and may attract inflammatory cells to the vascular
lesion [110]. The P2Y2 receptor enhances the oxidative burst
in human macrophages [111]. P2Y1 receptor deletion in
knockout mice reduces the atherosclerotic lesions and the
plaque area occupied by macrophages in ApoE knockout
mice [112]. Whether this is due to platelet inhibition, endo-
thelial or an inflammatory mechanism requires further studies.
ATP inhibits CD4+ T cell activation via an increase in
cyclic AMP (cAMP) probably via a P2Y11 receptor [113].
A T Pa c t i n go nP 2 Y 11 receptors regulates the maturation of
human monocyte-derived dendritic cells and induces immu-
nosuppression by inhibiting T-helper 1 cytokines and
promoting T-helper 2 cytokines [114, 115].
A polymorphism in the P2Y11 receptor has been shown
to have clinical importance by increasing the risk of
myocardial infarction [116]. The G-459-A polymorphism,
carried by one fifth of the population, causes an Ala-87-Thr
Purinergic Signalling (2008) 4:1–20 7substitution in the P2Y11 ATP receptor and increases the risk
of myocardial infarction by 21%. The odds ratio increased
stepwise depending on the number of Thr-87 alleles, and in
subgroups in which the genetic influence is known to be of
increased importance, family history of acute myocardial
infarction (AMI), early onset AMI or the combined group of
early onset AMI with family history. The mechanism by
which the polymorphism causes AMI seems to be coupled to
increased inflammation because the Thr-87 variant of the
P2Y11 receptor was coupled to elevated C-reactive protein
(CRP) levels. CRP is a marker of inflammation and an
independent prognostic risk factor for the development of
AMI [98]. Thus, the P2Y11 receptor is important in the
development of atherosclerosis via modulation of inflamma-
tion either via effects on T lymphocytes or macrophage cells.
Proinflammatory effects on the endothelium
Even though P2 receptor-mediated activation of the endo-
thelium stimulates release of NO, which inhibits inflamma-
tory cells, it is now well established that important
proinflammatory endothelial effects may also be triggered.
Aproinflammatorydysfunctionalendotheliumiscrucialinthe
recruitment of monocytes to the atherosclerotic plaque and in
thegeneralextravasationandloss ofperipheralresistanceseen
in sepsis. ATP stimulates neutrophil adherence to cultured
endothelial cells [117]. ATP stimulates release of IL-6, IL-8,
monocyte chemoattractant protein-1, growth-regulated onco-
gene α and increased expression of intercellular adhesion
molecule-1 in human microvascular endothelial cells [118].
UTP and ATP stimulate expression of proinflammatory
vascular cell adhesion molecule-1 (VCAM-1) in endothelial
cells through activation of the P2Y2 receptor and increases
the adherence of monocytic cells to human coronary
endothelial cells, an effect that was inhibited by anti-
VCAM-1 antibodies [119]. VCAM is important for the
recruitment of monocytes and lymphocytes. The VCAM
stimulation is caused by P2Y2 receptor-induced transactiva-
tion of the vascular endothelial growth factor receptor-2
[120]. These effects have been confirmed in an in vivo
neointima model, in which perivascular infusion of UTP
enhanced infiltration by macrophages [121].
Monocyte
VSMC
Contractile phenotype
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& chemotaxis
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Fig. 2 Functional roles of P2 receptors in the atherosclerotic
inflammatory plaque and during restenosis. See text for details.
Purines and pyrimidines acting on P2 receptors stimulate vascular
inflammation both by actions on the endothelial cell (EC) and by
effects on inflammatory cells. Furthermore, they stimulate vascular
smooth muscle cell (VSCM) proliferation, the conversion to synthetic
phenotype and production of matrix proteins. Mitogenic P2 receptors
are upregulated by growth factors and cytokines. IL interleukin, MCP-1
monocyte chemoattractant protein-1, ICAM-1 intercellular adhesion
molecule-1, TSP thrombospondin, IDO indoleamine 2,3-dioxygenase
8 Purinergic Signalling (2008) 4:1–20In conclusion, ATP and UTP stimulate several inflam-
matory responses known to be important for atherosclerosis
development (Fig. 2).
Restenosis and vascular smooth muscle cell
proliferative disease
VSMC proliferation contributes to plaque development, but
it is probably beneficial by stabilising the plaque and
forming a stronger fibrinous cap. However, there are several
situations in which VSMC proliferation is important in
vascular disease development: restenosis after balloon
angioplasty, diabetic microvascular disease, chronic allograft
rejection, pulmonary hypertension and possibly systemic
hypertension. The latter is suggested since sympathetic
nerves exert a trophic effect on vascular smooth muscle
[122]. ATP is a cotransmitter from sympathetic nerves [25]
and has been shown to be a more potent mitogen than the
other cotransmitters NA and NPY [123].
Extracellular ATP is a potent growth factor for VSMC
by activation of G protein-coupled P2Y receptors [12, 123–
125]. UTP is also mitogenic, acting on P2Y2 receptors [123],
as is UDP acting on P2Y6 receptors [124, 126, 127]. ATP is
synergistic with polypeptide growth factors (e.g. platelet-
derived growth factor, basic fibroblast growth factor) and
insulin [123, 124]. The signal transduction is mediated via
Gq proteins, phospholipase C and D, diacylglycerol, protein
kinase C, extracellular signal-regulated kinase, phosphatidy-
linositol-3 kinase, MAPK/ERK activity kinase, mitogen-
activated protein kinases and Rho [12, 128, 129]. Several
immediate early genes are activated and the cell is taken
through different phases of the cell cycle [125, 130]. Some-
times, as with UDP acting on P2Y6 receptors, progression is
stimulated to both the S and G2 phases, that is through the
whole cell cycle [127].
Mitogenic effects have been demonstrated in rat, porcine,
and bovine VSMC and cells from human coronary arteries,
aorta, and subcutaneous arteries and veins [12, 13, 124, 131].
The trophic effects on VSMC and the abundant sources for
extracellular ATP in the vessel wall make a pathophysiolog-
ical role probable in the development of atherosclerosis,
neointima formation after angioplasty, chronic allograft
rejection, pulmonary hypertension, diabetic microvascular
disease and possibly hypertension. In these processes
interaction between the VSMC and the matrix is important.
It is therefore interesting that the human P2Y2 receptor
contains an integrin-binding domain (RGD) in its first
extracellular loop and that interaction with integrins influ-
ences P2Y2 receptor-mediated activation of G proteins [132].
ATPstimulatesreleaseofmatrixmetalloproteinase-2(MMP-2)
from human aortic smooth muscle cells and MMP-2 has
been implicated in aortic aneurysm pathogenesis [133].
MMPs open up the matrix for migrating VSMC. ATP and
UTP are potent chemotactic agents stimulating VSMC
migration via P2Y2 and P2Y6 receptors [134]. These
mechanisms, together with growth-stimulating effects,
explain why perivascular infusion of UTP in a neointima
model enhanced neointimal development [121]. Overex-
pression of the ATP- and UTP-degrading enzyme
NTPDase1 reduces neointima development in rat aorta
[135]. Augmentation of NTPDase1 activity is an important
adaptive response for cardiac allograft survival, with
increased inflammation, platelet deposition and infarction
rates in NTPDase-deficient mice [136]. The mechanism is
dependent on increased expression of the atherosclerotic
matrix protein osteopontin [134, 137].
Diabetic microvascular disease
Sympathetic vascular dysfunction in early experimental
juvenile diabetes was recognised many years ago. Two
weeks after induction of streptozotocin diabetes in rats, there
was prejunctional impairment of sympathetic neurotransmis-
sion and impaired ATP-mediated endothelial function in
mesenteric arteries [138]. Altered relaxant responses to ATP
in the corpus cavernosum of men and rats with diabetes have
also been reported [139].
As mentioned above, red blood cells may stimulate
vasodilatation via release of ATP, which may be important in
maintainingperfusioninthemicrocirculation.Interestingly,in
erythrocytes from humans with type 2 diabetes ATP release is
impaired, which is consistent with the hypothesis that the
defect in erythrocyte physiology could contribute to the
vascular disease associated with this clinical condition [140].
High extracellular glucose releases ATP and/or UTP in
endothelial cells and pancreatic β cells [141, 142]. An
increase in glucose from 5 to 15 mmol/l results in a marked
increase in the proatherogenic nuclear factor of activated T
cells signalling pathway in VSMC [143]. The effect is
mediated via glucose-induced release of ATP and UTP,
which subsequently activate P2Y2 but also P2Y6 receptors
(after degradation to UDP). Thus, nucleotide release is a
potential metabolic sensor for the arterial smooth muscle
response to high glucose. Diabetic patients experience
microvascular disease characterised by increased wall-lumen
ratio, mainly because of an increase in VSMC and have
higher rates of restenosis after coronary angioplasty. High
glucose-induced release of extracellular nucleotides, acting
on P2Y receptors to stimulate VSMC growth via NFAT
(nuclear factor of activated T cells) activation, may provide a
link between diabetes and diabetic vascular disease [143].
In conclusion, ATP/UTP/UDP stimulate VSMC growth,
migration, release of MMPs and osteopontin that may
contribute to the development of restenosis, diabetic
microvascular disease, chronic allograft rejection, pulmo-
Purinergic Signalling (2008) 4:1–20 9nary hypertension and possibly systemic hypertension
(Fig. 2).
Vascular remodelling and angiogenesis
Vascular remodelling
P2 receptors may regulate VSMC phenotype and vice
versa, and P2 receptor expression is markedly altered during
phenotype changes [13]. The shift from a specialised
contractile VSMC phenotype into a proliferating, matrix-
producing, synthetic phenotype is a prerequisite for VSMC
pathogenesis in vascular disease. Pacaud and co-workers
found that the Ca
2+-mobilising effects of 2-methylthioATP
increased in VSMC during culture in serum, indicating
upregulation of P2Y1 receptors in the transition from
contractile to synthetic phenotype [144]. This was confirmed
at the mRNA level where P2Y2 receptors were found to be
upregulated, while P2X1 receptors were downregulated
[145]. Mitogenic P2Y receptors are upregulated while ion
channel receptors, with only contractile effects, are down-
regulated in the synthetic phenotype [145]. Growth factors,
cytokines and interestingly also ATP are potent stimulators
of P2Y2 receptor expression [146, 147]. Thus, factors of
importance in the development of vascular disease increase
mitogenic P2Y2 receptors; this is further supported by their
upregulation in neointima after balloon angioplasty [148,
149]. ATP has a dual concentration-dependent effect on
VSMC phenotype. Low ATP concentrations stimulate
expression of genes specific for the contractile phenotype,
while high ATP concentrations cause a phenotypic shift from
the contractile to the synthetic phenotype, and this shift is
dependent on a transient activation of protein kinase A,
which inhibits activation of a serum response factor [150].
This previously unrecognised mechanism also appears to be
important for the profound mitogenic effect of ATP. In intact
human blood vessels examined in vitro, shear stress
decreased contractile P2X1 receptor expression, but in-
creased the expression of mitogenic P2Y2 and P2Y6
receptors in VSMC [151]. This mechanism could promote
vascular growth and remodelling induced by shear stress as
an adaptive response to increased flow. P2X4 receptor
knockout mice are incapable of adaptive vascular remodel-
ling, that is, a decrease in vessel size in response to a chronic
decrease in blood flow [57].
Angiogenesis
Very little is known about the role of P2 receptors in
angiogenesis, but there are some studies suggesting their
involvement. Ischaemia stimulates release of ATP [7, 60]
and it has been shown to be a growth factor for endothelial
cells [13, 152]. ATP and UTP stimulate cytoskeletal
rearrangements with consequent cell migration of human
endothelial cells [153] and ATP stimulates vasa vasorum
neovascularisation in pulmonary arteries [154]. Newly
developed vascular endothelia express very high levels of
NTPDase1, also seen under hypoxic conditions [155].
NTPDase1 knockout mice exhibit disordered cellular
migration and angiogenesis [156].
Varicose veins
It has been suggested that cell lysis, consequent to P2X7
receptor-induced pore formation, contributes to the disor-
ganisation and decrease in contractile myocytes in the
media of varicose veins [157]. Upregulation of P2Y1 and
P2Y2 receptors and downregulation of P2X1 receptors on
smooth muscle of varicose veins is associated with a shift
from contractile to synthetic and/or proliferative roles; this
phenotypic change in smooth muscle leads to weakening of
vein walls and may be a causal factor in the development of
varicose veins [158], an interesting parallel to the receptor
changes seen in response to increased shear stress (see
above) [151].
Heart
ATP is released in the heart as a cotransmitter together with
catecholamines from sympathetic nerves, but it may also be
released from other sources in the heart such as endothe-
lium, platelets, RBC and ischaemic myocardium (Table 3)
[7, 60, 159]. P2 receptors are abundantly expressed in the
foetal human heart [160] as well as in the adult human heart
[60, 161].
Inotropy
In cardiomyocytes, ATP stimulates a pronounced positive
inotropic effectandmayalsoact insynergywithβ-adrenergic
agonists to augment myocyte contractility [60, 162–165].
ATP stimulates an increase in cytosolic calcium and evi-
dence for the involvement of inositol 1,4,5-trisphosphate
(IP3)-coupled P2Y2 receptors and ion channel P2X recep-
tors has been presented [162, 164–167]. Ap4A, probably
after degradation to ATP, increases force of contraction in
human ventricular trabeculae [168].
The inotropic effects of ATP are dependent on both IP3
and cAMP [169]. The inotropic effects of catecholamines
acting on β-receptors are mediated by an increase of cAMP
and antagonists of these receptors are important drugs for
the treatment of hypertension and reduce mortality in
congestive heart failure. Similarly, ATP stimulates an
increase in cAMP in cardiac myocytes and may act in
10 Purinergic Signalling (2008) 4:1–20synergy with the β1-adrenergic agonist, isoproterenol, by
differential activation of adenylyl cyclase isoforms [60,
170, 171]. However, the ATP receptor mediating this
increase in cAMP has not been related to any particular P2
receptor subtype in cardiac cells [60]. It could be the P2Y11
receptor that is additionally coupled to Gs and activates
adenylyl cyclase [60, 172–174]. mRNA for the P2Y11
receptor has been detected in the human heart at high levels
[161, 175].
The unstable agonist, UTP, has been shown to induce a
positive inotropic effect in rat atria and in rat and guinea pig
ventricular cardiomyocytes [164, 166, 176, 177]. Stable
UTP and UDP analogues induce a pronounced inotropic
effect on mouse cardiomyocytes [161]. The P2Y2 receptor
is the most abundantly expressed receptor with very low
levels of the P2Y4 receptor in the human heart [161],
suggesting that the inotropic effects of UTP are mediated
via P2Y2 receptors, while the UDP effects are mediated via
the P2Y6 receptor [161]. These mechanisms are mediated
via IP3-mediated signalling.
In conclusion, the inotropic effects in man are mediated
via P2Y2 and P2Y6 receptors and a P2Y11-like receptor
(Fig. 3). P2X receptors are probably also involved, since
several subtypes are expressed [60, 160], but it has not been
possible to perform a clear receptor characterisation due to
lack of selective antagonists.
Myocardial infarction
Using microdialysis, ATP in the interstitial space has been
estimated to be 40 nmol/l, but the levels may increase
markedly during electrical stimulation, ischaemia, challenge
with cardiotonic agents, increase in blood flow, mechanical
stretch and increased work load [60]. ATP is released from
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-
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UDP
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output
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c  Cardioprotective effects
UTP
NTPDase
Myocardial 
infarction
Fig. 3 Functional roles of
purines and pyrimidines acting
on P2 receptors in the regulation
of the heart. See text for details.
a ATP, UTP and UDP exert
inotropic effects on cardiomyo-
cytes leading to increased cardi-
ac output. b UTP and UDP
stimulate hypertrophy of cardi-
omyocytes, while ATP can have
apoptotic effects. c UTP protects
against ischaemic injury and
cardiomyocyte cell death. ATP-
degrading enzymes preserve en-
dothelial integrity and protect
against allograft rejection.
NTPDase nucleoside triphos-
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and ATP are released from the heart during cardiac
ischaemia [178] and patients with myocardial infarction
have higher plasma levels of both ATP and UTP [161, 179].
There is a significant increase in ectonucleotidase activity
(NTPDase1) in the hearts of patients with ischaemic heart
disease [180] that could represent a compensatory mecha-
nism against increased nucleotide levels during chronic
ischaemia.
Ischaemia-reperfusion provokes barrier failure of the
coronary microvasculature, leading to myocardial oedema,
ATP may protect against reperfusion-induced coronary
endothelial barrier damage and inhibition of ATP degrada-
tion enhances the stabilising effect of ATP on barrier
function [181].
The common P2Y11 ATP receptor polymorphism, Ala-
87-Thr, is associated with both increased CRP and
increased risk of developing myocardial infarction [116].
Based on this association, we hypothesise that the P2Y11
receptor plays an important role in cardiovascular biology
and in inflammatory disease (see above), causing myocar-
dial infarction via a proinflammatory effect. However,
increased inotropic effects may also contribute.
An interesting yin and yang situation for ATP and UTP
has been revealed regarding hypertrophic effects. UTP but
not ATP causes hypertrophic growth in neonatal cardio-
myocytes [182] (Fig. 3). In contrast, ATP inhibits hyper-
trophy and may even induce apoptosis and necrosis [163,
183]. The reason for the difference in effects could be due
to activation of P2X receptors or cAMP stimulation by ATP
[60, 161]. BothUTP andATPtransactivate epidermal growth
factor receptors, but only ATP stimulates the hypertrophic
marker genes atrial natriuretic peptide and myosin light chain
2[ 184]. Similarly, UTP but not ATP protects cultured
cardiomyocytes against hypoxic stress [185]. Since UTP is
released during preconditioning [178], a role for UTP in the
protective effects of preconditioning is plausible. Recently,
Yitzhaki and co-workers were able to demonstrate prominent
reductions in myocardial infarction size and improved rat
heart function in vivo, by a single intravenous bolus dose of
UTP before ischaemia [186]( F i g .3).
Congestive heart failure
There are several reports of alterations or adaptations of
purinergic signalling during congestive heart failure. The
positive inotropic effect of ATP is impaired in heart failure,
but reversed by the angiotensin-converting enzyme (ACE)
inhibitor imidapril [187]. The contractile responses for the
P2Y11 receptor agonist AR-C67085 are decreased in heart
failure, suggesting a downregulation of this receptor
function in cardiomyocytes in a similar manner as seen
for β1-receptors in congestive heart failure [169]. In human
hearts, only the P2X6 receptor was altered in congestive
heart failure [188]. In congestive heart failure P2X1
receptors are downregulated in VSMC in resistance arteries,
which could represent a protective response against the
increased sympathetic nerve activity and peripheral resis-
tance seen in congestive heart failure [189].
Several P2 receptors have been suggested as targets for
pharmacological treatment of congestive heart failure.
Overexpression of P2X4 receptors has a beneficial, life-
prolonging effect in a heart failure model [190]. Both ATP
and catecholamines are released from sympathetic nerves,
acting through cAMP-stimulating receptors to mediate
positive inotropic effects, stimulating the same intracellular
mechanisms as adrenergic β-receptors. It is possible that
agonists for the P2Y11 receptor could be used to improve
cardiac output in patients with circulatory shock. However,
an even more important drug candidate would be a P2Y11
receptor antagonist that may be beneficial in patients with
congestive heart failure. The extracellular pyrimidines UTP
and UDP may be inotropic factors in man, acting on P2Y2
and P2Y6 receptors stimulating the same intracellular
pathways as angiotensin II. Synthetic agonists could thus
be used as inotropic agents during circulatory shock and
antagonists may have effects similar to angiotensin II
receptor blockers, being beneficial in the treatment of
hypertension and congestive heart failure.
Chronotropy and arrhythmia
It has been difficult to determine the chronotropic effects of
ATP due to the dominating inhibitory effects of adenosine
on the AV node. We know that ATP increases the contractile
rate in neuron-myocyte co-cultures but the effect is markedly
reduced in non-innervated myocyte cultures [191]. ATP
could induce arrhythmia based on its increased automaticity
and early after-depolarisations [60]. The P2X1 receptor is
colocalised with connexin 43 in gap junctions that transmit
the contractile stimulus between cardiomyocytes [192].
However, so far no firm evidence exists of an important
role for P2 receptors for chronotropy or arrhythmia.
Platelets and coagulation
Platelets
ADP, released from erythrocytes or produced after ectonu-
cleotidase breakdown of ATP released from erythrocytes
and endothelial cells, was found to cause platelet aggrega-
tion as early as 1961, before the concept of P2 receptors
was conceived [193]. Later, the effects were attributed to a
single receptor, designated P2T, but it was not until 1998 that
the three receptors involved were characterised [194–196].
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ATP receptor (P2X1) are expressed on platelets [197, 198]
(Fig. 4). The P2Y12 receptor is coupled to inhibition of
cAMP. The molecular identifications of the P2Y12 receptor
and generation of knockout mice revealed highly prolonged
bleeding times, and their platelets aggregate poorly in res-
ponse to ADP and display a reduced sensitivity to thrombin
and collagen [199]. The P2Y1 receptor is responsible for
ADP-induced shape change and weak, transient aggregation
[200–202], while the P2Y12 receptor is responsible for the
completion and amplification of the response to ADP and to
all platelet agonists, including thromboxane A2,t h r o m b i n
and collagen. The platelets also express P2Y1 receptors that
have been shown in knockout mice to be of similar
importance as P2Y12 receptors [200, 203].
The physiological importance of the P2X1 receptor is not
fully elucidated. However, recent studies have demonstrat-
ed that P2X1 receptors can generate significant functional
platelet responses, independently and in synergy with other
receptor pathways. In addition, studies in transgenic
animals indicate an important role for P2X1 receptors in
platelet activation, particularly under conditions of shear
stress and thus during arterial thrombosis [204]. Synergistic
interaction between ATP and NA in stimulating platelet
aggregation may have significant clinical implications and
suggests a prothrombotic role for ATP in stress [205].
NTPDase1 is an important inhibitor of platelet activation.
Unexpectedly, NTPDase1-deficient mice had prolonged
bleeding times with minimally perturbed coagulation param-
eters. Platelet interactions with injured mesenteric vascula-
ture were considerably reduced in vivo and purified mutant
platelets failed to aggregate to standard agonists in vitro
[206]. This platelet hypofunction was reversible and associ-
ated with P2Y1 receptor desensitisation. In keeping with
deficient vascular protective mechanisms, fibrin deposition
was found at multiple organ sites in NTPDase1-deficient
mice and in transplanted cardiac grafts. Endothelial ADPase
activity is lost following ischaemia-reperfusion injury,
xenograft rejection and inflammation resulting in increased
levels of ATP and ADP [58, 207]. This may cause platelet
aggregation but also other effects, such as mitogenic effects
on VSMC. Infusion of systemic apyrase inhibits platelet
aggregation and prolongs xenograft survival [208]. This has
also been shown with adenoviral transfer of NTPDase1
[209]. NTPDase1 is also lost in vascular cardiac grafts
subjected to oxidant stress. NTPDase2 only degrades ATP to
ADP and has a prothrombotic effect. It is present in the
subendothelium and can shift the balance in a prothrombotic
direction after endothelial injury [210]( F i g .1).
ADP acting on P2Y12 receptors is not only important for
platelet activation, it also stimulates vasoconstriction. Stable
drugs with antagonistic effects on P2Y12 receptors, affecting
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Fig. 4 P2 receptor-mediated regulation of coagulation and platelet
aggregation. See text for details. ADP is an important mediator and
positive feedback mechanism for platelet aggregation. Activated
platelets stimulate coagulation, i.e. formation of a fibrin network. In
contrast, ATP, ADP and UTP release tissue plasminogen activator
(t-PA) from endothelial cells, resulting in degradation of the fibrin
network. At the same time plasminogen activator inhibitor (PAI-1)i s
also released from endothelial cells by ATP stimulation, in turn
inhibiting t-PA. Thus, P2 receptors regulate several balancing factors
in haemostasis. Ado adenosine
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benefit in their prevention of both thrombosis and vaso-
spasm [46].
Coagulation
The prothrombotic effect of ADP on the platelets is coun-
teracted by the effects of UTP and ATP on the endothelium
that stimulates a substantial release of tissue-type plasmin-
ogen activator (tPA) with fibrinolytic effects [51, 211]
(Fig. 4). To make the picture even more complex, ATP also
releases plasminogen activator inhibitor (PAI-1) which in
turn inhibits tPA [212]. Thus, P2 receptors are involved at
several stages of haemostasis, which is important for the
development of atherosclerosis and thrombotic occlusions
leading to myocardial infarction and stroke.
Clinical importance of P2 receptor-mediated regulation
of platelets
The first ADP inhibitors, ticlopidine and clopidogrel, were
developed before the cloning and identification of the platelet
ADP receptors. Later, it was concluded that they were
prodrugs, converted in the liver to a metabolite that binds
irreversibly to the P2Y12 receptor resulting in non-competitive
antagonism.
Ticlodipine has the disadvantage of a small risk of
neutropaenia, so that clinically so far the most important
Table 4 Cardiovascular dis-
ease targets
The table presents possible
targets for the development of
new pharmaceutical com-
pounds for the treatment of
cardiovascular diseases
Receptor
target
Agonist/antagonist activity
of therapeutic drug
Disease
Vascular smooth muscle cell
P2Y2 Antagonist Hypertension, restenosis, diabetic microvascular
disease, subarachnoidal bleeding
P2Y6 Antagonist Hypertension, restenosis, diabetic microvascular
disease, subarachnoidal bleeding
P2Y12 Antagonist Hypertension, vasospasm
P2X1 Antagonist Hypertension, migraine, subarachnoidal bleeding
P2Y6 Agonist Migraine
SolNTPDase1 Ectonucleotidase Restenosis, xenograft rejection
Endothelial cell
P2Y2 Antagonist Atherosclerosis, inflammation
P2X4 Antagonist Vascular remodelling (cancer?), preeclampsia
Heart
P2Y2 Antagonist Congestive heart failure
P2Y6 Antagonist Congestive heart failure
P2Y11 Antagonist Congestive heart failure, myocardial infarction
P2Y2 Agonist Shock, reduced cardiac output, cardiac protection
P2Y6 Agonist Shock, reduced cardiac output
P2Y11 Agonist Shock, reduced cardiac output
SolNTPDase1 Ectonucleotidase Heart transplantation, myocardial infarction
Inflammatory cells
P2Y2 Antagonist Atherosclerosis
P2Y11 Antagonist Atherosclerosis
P2X7 Antagonist Atherosclerosis
Platelets
P2Y1 Antagonist Myocardial infarction, stroke, peripheral artery disease
P2Y12 Antagonist Myocardial infarction, stroke, peripheral artery disease
P2X1 Antagonist Myocardial infarction, stroke, peripheral artery disease
SolNTPDase1 Ectonucleotidase Myocardial infarction, stroke, peripheral artery disease
Red blood cell
P2Y13 Antagonist Improved peripheral circulation
P2X7 Antagonist Shock
Perivascular nociceptive sensory nerves
P2Y1 Agonist Migraine, vascular pain
P2X3 Antagonist Migraine, vascular pain
Perivascular sympathetic nerves
P2Y1 Agonist Hypertension
P2X2 Antagonist Hypertension
14 Purinergic Signalling (2008) 4:1–20contribution of drug development aimed at P2 receptors has
been the beneficial effects of the platelet ADP receptor
antagonist clopidogrel in atherosclerotic disease. In the
CAPRIE trial, clopidogrel was even more effective com-
pared to aspirin in preventing myocardial infarctions [213].
Clopidogrel, as an addition to aspirin, turned out to be
necessary to prevent acute in-stent thrombosis in percuta-
neous coronary interventions. The CURE trial demonstrated
that the addition of clopidogrel to aspirin reduced clinical
events by 20% in acute coronary syndromes [213, 214]. This
has also been shown for ST-elevation myocardial infarctions
(COMMIT, CLARITY). However, long-term secondary
prevention in high-risk groups with clopidogrel added to
aspirin did not have significant benefits (CHARISMA).
Clopidogrel combined with aspirin reduces cerebral em-
boli in patients undergoing carotid endarterectomy [215].
Clopidogrel (Plavix®) is now a blockbuster drug and one of
the most sold drugs worldwide to the benefit of atheroscle-
rotic patients. Nevertheless, clopidogrel is a rather weak
antagonist at P2Y12 receptors with variable effects, often
referred to as clopidogrel resistance. Newer P2Y12 receptor
antagonists, such as prasugrel and AZD6140, have a stronger
more consistent effect and are currently being studied in
major clinical trials (TRITON and PLATO).
Clinical importance of purinergic signalling
in cardiovascular disease: future directions
The P2 receptor family provides opportunities for drug
development (see Table 4). The large number of receptor
subtypes and the increasing knowledge of their tissue
distributions may make it possible to target a specific
cardiovascular organ with limited side effects. So far, only
P2Y12 receptor antagonists have been explored in patients,
but with extraordinary success. Clopidogrel is one of the
most prescribed drugs in the world for the treatment of
thrombosis, stroke and myocardial infarctions in millions of
patients. The following compounds, prasugrel and
AZD6140, are even more potent P2Y12 receptor antagonists
with clinical benefits currently being tested in phase III
trials. Improved platelet inhibition can also be achieved
with antagonists against the other two P2 receptors on
platelets. Studies in P2Y1 and P2X1 receptor knockout mice
and experimental thrombosis models using selective P2Y1
and P2X1 receptor antagonists have shown that, depending
on the conditions, these receptors could also be potential
targets for new antithrombotic drugs.
ATP, UTP and UDP, acting on P2Y2 and P2Y6 receptors,
are potent stimulators of inflammation, VSMC proliferation
and migration. Antagonists to these receptors may be
explored to protect against atherosclerosis, restenosis after
balloon angioplasty, chronic transplant rejection and dia-
betic microvascular disease.
It is possible that hypertension and pulmonary hyper-
tension could be treated with P2X1,P 2 Y 2,P 2 Y 6 or P2Y12
receptor antagonists. In the heart P2Y2, P2Y6 and P2Y11
receptor antagonists may have similar beneficial roles as
angiotensin inhibition or β-blockers in the treatment of
congestive heart failure. In the acute phase of a myocardial
infarction, a UTP analogue could protect cardiomyocytes
and limit infarct size. A polymorphism in P2Y11 receptors
could be considered as a prognostic marker to identify
patients at risk of myocardial infarction and drugs aimed at
the receptor could be explored to prevent myocardial
infarction.
A promising strategy would be to use soluble NTPDase to
prevent thrombosis, restenosis and xenograft transplantation.
SolNTPDase1 protects against brain damage in a stroke
model and a human genetically engineered solNTPDase has
been developed that could be used in clinical trials. Possible
clinicalindicationscouldbestroke,myocardialinfarctionand
transplantation. P2X3 receptor antagonists could be used
against migraine and vascular pain [see 19, 26].
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